Scarica l'app Stockscreener
15.78
0.06%
0.010
Pre-mercato:
15.67
-0.11
-0.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a Potential 43.7% Upside in the Biotech Sector - DirectorsTalk Interviews
(SRPT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Sarepta Therapeutics (SRPT) Q1 earnings and revenues top estimates - MSN
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
ING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Exclusive | Startup Hunts for a Better Duchenne Gene Therapy - WSJ
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Is Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook? - Yahoo Finance
SRPT: Strong financials and pipeline progress drive confidence in growth and regulatory stability - TradingView
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy - Yahoo Finance
SRPT: Strong financials and pipeline progress drive growth, with pivotal data expected this year - TradingView
SRPT vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
SRPT: Strong financials and pipeline progress drive confidence amid leadership transition - TradingView
Sarepta Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors - TMX Newsfile
Sarepta Therapeutics, Inc. $SRPT Shares Sold by BNP Paribas Financial Markets - MarketBeat
A Look At Sarepta Therapeutics (SRPT) Valuation After New Shelf Registration For Potential Share Offering - Sahm
Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy - Insider Monkey
Sarepta Therapeutics (SRPT) director receives 16,875 RSUs equity grant - Stock Titan
Sarepta Therapeutics (SRPT) director receives 16,875-share RSU equity award - Stock Titan
Sarepta Shareholders Approve 2026 Equity and ESPP Plans - The Globe and Mail
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report? - Yahoo Finance
Sarepta faces earnings test as ELEVIDYS slows, siRNA pipeline builds - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Sarepta faces earnings test as ELEVIDYS slows, siRNA pipeline builds By Investing.com - Investing.com Nigeria
Sarepta (SRPT) awards director Barry Richard 16,875 RSUs - Stock Titan
Sarepta Therapeutics Adopts 2026 Equity Incentive and Employee Stock Purchase Plans – 8-K SEC Filing Summary - Minichart
Earnings call transcript: Sarepta’s Q1 2026 earnings beat expectations - Investing.com
Sarepta Q1 2026 slides: profitability returns amid commercial reset - Investing.com
Sarepta (SRPT) investors approve 2026 stock plans, director slate and KPMG - Stock Titan
SRPT: All proposals passed amid board focus on stability, CEO succession, and performance improvement - TradingView
Acting US FDA chief meets with rare disease groups to mend fences - marketscreener.com
Sarepta Therapeutics, Inc. (AB3A.F) Stock Price, News, Quote & History - Yahoo Finance
SRPT DEADLINE TOMORROW: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class ActionSRPT - TMX Newsfile
Sarepta Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
Responsive Playbooks and the SRPT Inflection - Stock Traders Daily
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion - marketscreener.com
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Number of shareholders of Sarepta Therapeutics, Inc. – MIL:1SRPT - TradingView
Sarepta Therapeutics Outlines 2026 Priorities on Strong Cash PositionPeak Earnings Alert - newsline.com
Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | PTC Therapeutics, Sarepta Therapeutics, Taiho Pharma, Regenxbio, Fibrogen, Roche - Barchart.com
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo Finance
In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities - Insider Monkey
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):